Armata Pharma receives FDA EOP2 support for AP-SA02 Phase 3 in S. aureus bacteremia

Armata Pharmaceuticals, Inc.

• FDA confirmed Phase 2a diSArm data support advancement of AP-SA02 to a Phase 3 superiority study.
• Phase 3 study anticipated to initiate in the second half of 2026 in complicated S. aureus bacteremia.
• First bacteriophage company to advance a clinical candidate to Phase 3 for this indication.
• FDA is amenable to a request for Qualified Infectious Disease Product (QIDP) designation; Armata has submitted the request.
• Partnership with U.S. Department of Defense and significant shareholder Innoviva continues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.